Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.51 |
| ▸ | MET | P08581 | 11/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768136 | 0.89 | ROCK2 (0.58) | MAP4K1METROCK2CYP3A4AXL | |
| SCHEMBL4775389 | 0.80 | MET (0.71) | METKDRFLT3 | |
| SCHEMBL20589202 | 0.79 | BRAF (0.48) | BRAFMAP4K1ROCK2KDR | |
| SCHEMBL29837311 | 0.77 | TRPA1 (0.55) | MAP4K1METROCK2CYP3A4AXL | |
| SCHEMBL4768031 | 0.77 | TRPA1 (0.55) | MAP4K1METROCK2CYP3A4AXL | |
| SCHEMBL20588042 | 0.76 | MAP4K1 (0.62) | MAP4K1METROCK2CYP3A4AXL | |
| SCHEMBL25243851 | 0.75 | FLT3 (0.61) | BRAFFLT3 | |
| SCHEMBL30486122 | 0.75 | FLT3 (0.61) | BRAFFLT3 | |
| SCHEMBL4767974 | 0.75 | MET (0.54) | MAP4K1METROCK2CYP3A4KDR | |
| SCHEMBL4772462 | 0.75 | ROCK2 (0.59) | MAP4K1METROCK2CYP3A4AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| EP-1751153-B1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1751153-B1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| WO-2005097790-A1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | TNK2, ROCK1, ROCK2 | BRAF 228/4885MAP4K1 57/4885MET 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.